New pharmacological treatment to preserve/improve renal function after ischemic kidney surgery

Description

experimental trial in pigs; use of neprilysin+valsartan (lcz696, comercial name : Entresto/Novartis lab) to prolong the effects of natriuretic peptides at kidney level after partial nephrectomies to improve renal outcomes such us creatinine blood levels, glomerular filtration rate and reduce the incidence of acute renal insufficiency and the cumulative risk of end stage kidney disease.
StatusActive
Effective start/end date03/09/201831/08/2021

Keywords

  • natriuretic peptides
  • lcz696
  • entresto
  • partial nephrectomy
  • acute kidney insufficiency
  • end stage kidney disease
  • neprilysin
  • sacubitril
  • valsartan